EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER
Although many currently known molecular targets are characterized by organ specificity, they can be found in various types of tumors. Molecular diagnostic techniques can be used to help select patients who are most likely to benefit from target therapy. Case presentation. We describe the case of a 3...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2020-03-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1334 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849408371641286656 |
|---|---|
| author | A. A. Paichadze L. V. Bolotina E. Y. Karpenko T. V. Ustinova A. L. Kornietskaya A. D. Kaprin A. A. Fedenko |
| author_facet | A. A. Paichadze L. V. Bolotina E. Y. Karpenko T. V. Ustinova A. L. Kornietskaya A. D. Kaprin A. A. Fedenko |
| author_sort | A. A. Paichadze |
| collection | DOAJ |
| description | Although many currently known molecular targets are characterized by organ specificity, they can be found in various types of tumors. Molecular diagnostic techniques can be used to help select patients who are most likely to benefit from target therapy. Case presentation. We describe the case of a 38-year-old patient with advanced gastric cancer with peritoneal dissemination. On december 11, 2014, the patient underwent palliative subtotal gastrectomy followed by 18 cycles of chemotherapy (xelOx) and radiotherapy. On February 2, 2017, percutaneous transhepatic cholangiostomy of the left lobe bile duct was performed. in May 2017, the stent was inserted into the common bile duct due to bile duct stenosis. three months later, disease progression (multiple liver metastases) occurred, and chemotherapy with paclitaxel was given in a weekly schedule. therapy with crizotinib was administered 3 months after determining the alK mutation. the duration of treatment was 8 months with satisfactory tolerability. Conclusion. target therapy with krizotinib seems to be an effective treatment for alK-positive tumors. |
| format | Article |
| id | doaj-art-61438f71b6e749f3a883a0bcc0bffeef |
| institution | Kabale University |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2020-03-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-61438f71b6e749f3a883a0bcc0bffeef2025-08-20T03:35:48ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682020-03-0119114114610.21294/1814-4861-2020-19-1-141-146722EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCERA. A. Paichadze0L. V. Bolotina1E. Y. Karpenko2T. V. Ustinova3A. L. Kornietskaya4A. D. Kaprin5A. A. Fedenko6National Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationNational Research Medical Radiological Center, Ministry of Healthcare of Russian FederationAlthough many currently known molecular targets are characterized by organ specificity, they can be found in various types of tumors. Molecular diagnostic techniques can be used to help select patients who are most likely to benefit from target therapy. Case presentation. We describe the case of a 38-year-old patient with advanced gastric cancer with peritoneal dissemination. On december 11, 2014, the patient underwent palliative subtotal gastrectomy followed by 18 cycles of chemotherapy (xelOx) and radiotherapy. On February 2, 2017, percutaneous transhepatic cholangiostomy of the left lobe bile duct was performed. in May 2017, the stent was inserted into the common bile duct due to bile duct stenosis. three months later, disease progression (multiple liver metastases) occurred, and chemotherapy with paclitaxel was given in a weekly schedule. therapy with crizotinib was administered 3 months after determining the alK mutation. the duration of treatment was 8 months with satisfactory tolerability. Conclusion. target therapy with krizotinib seems to be an effective treatment for alK-positive tumors.https://www.siboncoj.ru/jour/article/view/1334chemotherapytarget therapyсrizotinibadvanced gastric cancer |
| spellingShingle | A. A. Paichadze L. V. Bolotina E. Y. Karpenko T. V. Ustinova A. L. Kornietskaya A. D. Kaprin A. A. Fedenko EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER Сибирский онкологический журнал chemotherapy target therapy сrizotinib advanced gastric cancer |
| title | EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER |
| title_full | EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER |
| title_fullStr | EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER |
| title_full_unstemmed | EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER |
| title_short | EFFICACY OF TARGET THERAPY WITH CRIZOTINIB IN A PATIENT WITH ALK-POSITIVE ADVANCED GASTRIC CANCER |
| title_sort | efficacy of target therapy with crizotinib in a patient with alk positive advanced gastric cancer |
| topic | chemotherapy target therapy сrizotinib advanced gastric cancer |
| url | https://www.siboncoj.ru/jour/article/view/1334 |
| work_keys_str_mv | AT aapaichadze efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT lvbolotina efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT eykarpenko efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT tvustinova efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT alkornietskaya efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT adkaprin efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer AT aafedenko efficacyoftargettherapywithcrizotinibinapatientwithalkpositiveadvancedgastriccancer |